Portfolio

Developing novel antibacterials for Gram negative infections

Achaogen (NASDAQ: AKAO) is a clinical stage company focused on the discovery and development of novel antibiotics for multi-drug resistant (MDR) Gram negative bacteria. The company’s lead asset, plazomicin, is in late-stage development to treat MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae that have been classified as an “urgent threat” by the CDC. Achaogen completed its IPO in 2014.

IPO in 2014 (NASDAQ: AKAO)

Frazier Life Sciences-founded biopharmaceutical company focused on developing novel therapies for respiratory diseases, starting with chronic obstructive pulmonary disease (COPD)

AirNexis is advancing AN01, a dual phosphodiesterase 3/4 (PDE3/4) inhibitor designed to combine bronchodilation with anti-inflammatory activity to address airflow limitation and chronic inflammation in COPD. The company in-licensed this Phase 2 clinical asset from Haisco Pharmaceutical Group and is progressing its global development outside of Greater China following an oversubscribed $200 million Series A financing led by Frazier Life Sciences.

Creating point-of-care, enzyme-based medical nutrition products to improve fat absorption

Alcresta is a specialty pharmaceuticals company focusing on discovering and developing a new generation of enzyme-based products that improve digestion and absorption of important nutrients. The company’s lead program is a point-of-care, enzyme-based product that improves the bioavailability of long chain fatty acids (such as DHA, EPA, and AA) for patients with impaired pancreatic output. Compromised pancreatic function is a complication of many diseases such as cystic fibrosis, chronic pancreatitis, and cancer as well as developmental immaturity, and Alcresta’s products are aimed at meeting the nutritional needs of these patients.

Acquired by Linden Capital in 2024)

Antibody-drug conjugate (ADC) company developing therapeutics leveraging multiple payload classes for the treatment of solid tumors

Alentis is a clinical-stage company developing therapeutics for solid tumors and fibrosis. The company’s lead programs are antibody drug conjugates leveraging multiple payload classes to target claudin 1 (CLDN1) across a variety of cancers.

Oral small molecules for orphan diseases including hypophosphatasia (HPP).

Alesta Therapeutics is developing small molecule therapeutics to treat orphan diseases. The company’s intial focus is on hypophosphatasia (HPP) and related disorders.

Orally delivered non-systemic enzymes focusing on nephrologic and urologic conditions

Allena is developing protein therapies delivered orally to the gastrointestinal tract that reduce toxic metabolites without being absorbed into the bloodstream. The company’s lead candidate ALLN-177 is an orally administered recombinant oxalate degrading enzyme for the chronic management of hyperoxaluria and kidney stones. The drug is the first pharmacologic treatment to demonstrate a statistically significant reduction in urinary oxalate excretion, a positive finding for patients with hyperoxaluria.

IPO in 2017 (NASDAQ: ALNA)

Developing orally delivered protein therapeutics for cystic fibrosis patients

Alnara was founded in 2008 to develop orally-delivered, non-systemic enzyme therapeutics that remain active through the gastrointestinal tract. The company’s lead product, liprotamase, is a soluble, stable, and non-porcine derived enzyme product for treatment of patients with low digestive enzyme levels due to cystic fibrosis and potentially other diseases. Alnara was acquired by Eli Lilly in 2010.

Acquired by Eli Lilly & Co. in 2010

Focused on advancing a portfolio of novel radiotherapeutics and diagnostics

Alpha-9 Theranostics is a clinical-stage company developing a portfolio of radiolabeled imaging and therapeutic molecules for solid and hematologic malignancies. These differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of using targeted radiation to improve the lives of patients affected by cancers.

Creating novel protein-based immunotherapies to treat cancer and autoimmune disorders

Alpine Immune Sciences is developing next-generation immunotherapies to treat cancer and autoimmune disorders. Alpine’s proprietary technology platforms enable the development of engineered proteins optimized to modulate multiple immune cell receptors within the immune synapse. Alpine was founded by a veteran team of biotechnology executives and scientific experts with expertise in developing recombinant protein-based immunotherapies. Alpine was acquired by Vertex in 2024.

Acquired by Vertex Pharmaceuticals in 2024

Improving therapies for a range of human genetic diseases focusing on lysosomal storage diseases

Amicus (NASDAQ: FOLD) is focused on the discovery and development of therapeutics for rare and orphan diseases. The company’s pipeline is based on its pharmaceutical chaperone technology to stabilize mutated proteins that are unstable, misfolded, or unfolded. Amicus completed its IPO on NASDAQ in 2007.

IPO in 2007 (NASDAQ: FOLD)

Focused on the discovery and development of masked T cell engager therapeutics in oncology

Amunix Pharmaceuticals is a privately held drug discovery and development company with two proprietary technologies, XTEN® and ProTIA, that enable the rapid generation of protein therapeutics that are engineered to be fit for purpose. In 2018, Frazier acquired a majority stake in Amunix and is committed to building a leading biotechnology company devoted to discovering and developing innovative therapeutics for patients with cancer and other serious diseases. The Amunix platform has been validated through multiple collaborations with leading biopharmaceutical companies, including Celgene, Genentech, Janssen, Roche, Bioverativ, and Baxter. The company was acquired by Sanofi in 2021.

Acquired by Sanofi in 2021

Pioneering the development of therapeutic antibodies generated through natural biology

AnaptysBio is developing novel antibody therapeutics for inflammatory diseases and immuno-oncology indications. The company’s products are built on a core in vitro technology that reproduces the body’s natural mechanism of antibody generation (somatic hypermutation) to rapidly produce high affinity, high specificity antibodies. AnaptysBio has built a pipeline of partnered and proprietary programs against novel targets, including Jemperli (dostarlimab) which was approved in 2021. Anaptys completed its IPO in 2017.

IPO in 2017 (NASDAQ: ANAB)

Clinical-stage biopharmaceutical company developing novel biologic therapies to improve musculoskeletal health and treat serious skeletal disorders.

Angitia has leveraged deep expertise in bone biology and rational therapeutic design to develop a pipeline of biologic product candidates designed to modulate key pathways in bone formation and repair. Programs include AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1 and being evaluated in Phase 2 clinical trials for postmenopausal osteoporosis and osteogenesis imperfecta, respectively.

Discovering and developing transformative therapies for challenging disorders of the brain and nervous system

A spin-out of Naurex Pharmaceuticals, Aptinyx is discovering and developing innovative treatments for neurological disorders where there is a significant unmet need for improved therapies. The company is building a platform of novel compounds that precisely modulate the N-methyl-D-aspartate (NMDA) receptor, which plays a pivotal role in brain and nervous system function and disorders. Aptinyx is led by several members of the Naurex team, who successfully led the sale of Naurex to Allergan for a total consideration of up to $1.71B in 2015.

IPO in 2018 (NASDAQ:APTX)

Drug discovery company with a novel “C-H activation” chemistry platform to enable rapid, rational design of small molecule drugs

Architect Therapeutics is developing oral therapies by targeting disease drivers that have been difficult-to-drug with existing chemistry. Its approach transforms dormant carbon-hydrogen (C-H) bonds – the most common bonds in small molecules – into powerful building blocks of novel drug architectures.

Discovering, developing, and commercializing innovative topical medicines for the treatment of skin diseases

Arcutis is a Frazier-founded company developing potentially best-in-class topical medicines for the treatment of skin diseases. The company’s lead program (Zoryve), which was initially approved by FDA in 2022, is a topical formulation of roflumilast. Zoryve has gained FDA approvals to treat psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis in various formulations and product strengths. Arcutis completed its IPO in 2020.

IPO in 2020 (NASDAQ:ARQT)

Immunology-focused biopharmaceutical company developing therapies for inflammatory and autoimmune diseases

Arena Pharmaceuticals advanced a diverse pipeline of small-molecule and biologic drug candidates targeting immune-mediated and inflammatory disorders. Its lead programs included etrasimod, a selective S1P receptor modulator for ulcerative colitis, Crohn’s disease, and other autoimmune conditions, and temanogrel, a serotonin 2A receptor antagonist for microvascular dysfunction. Arena’s focus on precision immunology and efficient clinical execution culminated in its acquisition by Pfizer in 2022, supporting the global development and commercialization of etrasimod for patients with chronic inflammatory diseases.

Acquired by Pfizer in 2021

Developing novel products to eradicate tumors

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel cytokine-based therapeutics that activate the immune system of cancer patients to recognize and eradicate tumors. The company’s pipeline includes product candidates aimed at treating a variety of cancers with significant unmet medical need in combination with standard of care and emerging immunotherapies. ARMO completed its IPO on NASDAQ in early 2018 and was acquired by Eli Lilly & Company in mid-2018.

IPO in 2018; Acquired by Eli Lilly in 2018

Targeted small molecule therapeutics for treating cancer

Array (NASDAQ: ARRY) is a drug discovery and development company focusing on first-in-class small molecule therapeutics for cancer. The company has completed partnerships with a number of leading biopharmaceutical companies, including fellow Frazier portfolio company VentiRx. Array completed its IPO on NASDAQ in 2000.

IPO in 2000 (NASDAQ: ARRY)

Personalized cell therapy for Parkinson disease

Aspen Neuroscience is developing the potentially first autologous neuron replacement therapy to treat Parkinson disease. The company’s clinical development encompasses both an autologous neuron replacement therapy in sporadic Parkinson disease (ANPD001) and a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease (ANPD002).

Discovering and developing small format biologics, including multi-specifics, for inflammatory and autoimmune disorders

Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages AttobodyTM, Alamar Biosciences’ novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration.

Developing therapeutics for viral and liver diseases, including hepatitis delta (HDV)

Bluejay Therapeutics is a clinical-stage company developing therapeutics for patients with viral and liver diseases. The company’s lead product, BJT-778, is a monoclonal antibody against hepatitis B surface antigen (anti-HBsAg) to treat hepatitis delta (HDV) and in combinations to pursue a functional cure for hepatitis B (HBV). BJT-778 received PRIME Designation from the EMA for the treatment of HDV in 2024 and FDA Breakthrough Therapy Designation in 2025.

Acquired by Mirum Pharmaceuticals in 2026

Clinical-stage biopharmaceutical company developing novel therapies for hypertrophic cardiomyopathy and other cardiovascular conditions.

Braveheart is advancing BHB-1893, a selective cardiac myosin inhibitor engineered to address the underlying hypercontractility of hypertrophic cardiomyopathy, a genetic heart disorder with significant unmet need. The company is progressing this investigational small molecule through late-stage clinical development with the goal of improving heart performance and patient outcomes.

Genetic medicine company developing therapies for rare diseases and genetically defined conditions

BridgeBio Pharma is dedicated to discovering, developing, and delivering medicines for patients suffering from genetic diseases. The company’s lead program, Acoramidis, is a next-generation TTR stabilizer for transthyretin amyloidosis (ATTR), a progressive and life-threatening disease affecting the heart and peripheral nerves. In Phase 3 studies, acoramidis demonstrated robust efficacy in improving functional and survival outcomes, positioning it as a potential best-in-class therapy for ATTR cardiomyopathy. Beyond acoramidis, BridgeBio continues to advance a broad pipeline of potentially transformational medicines for patients with rare diseases.

Developing and commercializing Ofirmev, a non-opioid therapeutic for post-operative pain

Cadence was a hospital-focused, specialty pharmaceuticals company developing and commercializing Ofirmev, the first and only IV formulation of acetaminophen for mild-to-moderate pain. Cadence achieved FDA approval for Ofirmev in 2011 and launched the drug to provide post-operative hospital patients a new non-opioid therapy for pain. Ofirmev generated >$100M in sales in its third year of launch, and Cadence was acquired by Mallinckrodt in 2014.

IPO in 2006; Acquired by Mallinckrodt Pharmaceuticals in 2014

Discovering and developing novel peptides for diabetes and related metabolic diseases

Calibrium is focused on new approaches to treat diabetes and related metabolic disorders. The Calibrium leadership team (including co-founders Richard DiMarchi and Fritz French) was previously affiliated with Marcadia Biotech, which was also focused on novel diabetes therapeutics and sold to Roche in 2010.

Acquired by Novo Nordisk in 2015

Transforming the treatment of hematologic malignancies through innovative and targeted therapeutics

Calistoga was founded in 2006 to develop the first selective inhibitor of PI3K-delta, a critical signaling molecule for many types of hematologic cancers. Calistoga’s outstanding team brought the company’s lead asset (then called CAL-101) into clinical studies and immediately achieved remarkable early activity in patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). On the basis of this clinical activity, Gilead acquired Calistoga in 2011. Following futher development (and Breakthrough Therapy designation from the FDA), Gilead achieved both FDA and EU approval in 2014 for CAL-101 (as brand name Zydelig) to treat CLL, FL, and small lymphocytic lymphoma (SLL, US-only).

Acquired by Gilead Sciences in 2011

Meeting the growing threat of drug-resistant Gram negative bacteria through innovative therapeutics

Calixa was founded in 2007 to develop novel antibiotics to treat serious hospital-based bacterial infections. The company’s lead asset was a combination of a novel 5th-generation cephalosporin with a beta lactamase inhibitor, and the drug displayed an outstanding spectrum of activity against Gram negative bacteria including resistant isolates. Calixa was acquired by Cubist Pharmaceuticals in 2009, and Cubist gained approval for Calixa’s lead asset (brand name Zerbaxa) in 2014 to treat complicated intra-abdominal infections and complicated urinary tract infections.

Acquired by Cubist Pharmaceuticals in 2009

Next-gen antibody-drug conjugate (ADC) platform with dual payload technology

Callio Therapeutics is a Seattle & Singapore-based company that is developing dual payload antibody-drug conjugate (ADC) therapeutics using proprietary technology that was licensed from Hummingbird Bioscience. Callio’s dual payload ADCs aim to address payload resistance to existing payload classes and also to enhance ADC efficacy by hitting multiple pathways in solid tumors.

Metabolic disease company developing novel incretin-based therapies for obesity and diabetes

Carmot Therapeutics designed a portfolio of innovative small-molecule drugs targeting the incretin system to treat obesity, diabetes, and related metabolic disorders. Its lead programs included CT-388, a dual GLP-1/GIP receptor agonist demonstrating significant weight loss and glycemic control in early clinical studies. Carmot’s proprietary Chemotype Evolution discovery platform enabled the rapid identification of optimized incretin modulators with differentiated pharmacologic profiles. The company was acquired by Roche in 2023.

Acquired by Roche in 2023

Neuroscience-focused biopharmaceutical company developing therapies for psychiatric and neurological disorders

Cerevel Therapeutics is advancing a deep pipeline of novel neuroscience drugs targeting diseases such as schizophrenia, Parkinson’s disease, and epilepsy. The company’s portfolio includes emraclidine, a muscarinic M4-selective positive allosteric modulator, and tavapadon, a dopamine D1/D5 partial agonist for Parkinson’s disease. Cerevel’s approach integrates cutting-edge neurobiology with targeted drug design to address unmet needs in brain health. The company was acquired by AbbVie in 2024.

Acquired by AbbVie in 2023

Addressing MRSA and other serious bacterial infections with a novel antibiotic therapeutic

Cerexa focused on next-generation antibiotics to treat the rising threat of bacterial resistance to conventional antibiotics. The company’s lead compound (ceftaroline) is a 5th-generation cephalosporin that exhibits bactericidal activity against highly resistant strains of gram-positive bacteria, including MRSA. Following positive clinical proof-of-concept, Cerexa was acquired by Forest Laboratories in 2007. Following acquisition, Forest gained FDA approval in 2010 (brand name Teflaro) and EU approval in 2012 (brand name Zinforo) for treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Acquired by Forest Pharmaceuticals in 2007

Novel therapeutics to prevent and treat life-threatening viral infections

Chimerix (NASDAQ: CMRX) is an anti-viral drug discovery and development company leveraging a proprietary lipid-conjugate technology to enhance oral absorption and improve antiviral potency. The company’s lead product is brincidofovir, an oral broad-spectrum antiviral with potent activity against DNA viruses. Brincidofovir is being developed to prevent and treat infections in a number of patient populations, including prevention of cytomegalovirus in transplant settings and treatment of adenovirus. Chimerix completed its IPO on NASDAQ in 2013.

IPO in 2013 (NASDAQ: CMRX)

Kidney-focused development company with two novel mechanisms to treat IgA nephropathy

Frazier Public Fund’s first investment was in Chinook, and Frazier continued to build its position through multiple financings to support the development of Atrasentan and BION-1301 for IgA nephropathy. Frazier also co-led a spinout of Chinook into a new private company, SanReno Therapeutics. Chinook was acquired by Novartis in 2023.

Acquired by Novartis in 2023

Addressing serious viral and fungal infections through a pipeline of innovative therapeutics

Cidara (NASDAQ: CDTX) is focusing on the discovery, development, and commercialization of therapeutics to treat serious fungal and viral infections. Cidara was named to FierceBiotech’s “Fierce 15” in 2014, and the company priced its IPO in 2015.

IPO in 2015 (NASDAQ: CDTX)

Realizing the promise of personalized medicines for cancer

Clovis Oncology (NASDAQ: CLVS) is developing targeted cancer therapies in combination with companion diagnostics to ensure that the right drug gets to the right patients. The company achieved FDA approval for Rubraca (rucaparib) in 2016 to treat women with advanced ovarian cancer whose tumors have a BRCA mutation. Clovis completed its IPO in 2011.

IPO in 2011 (NASDAQ: CLVS)

Advancing the next generation of abuse-deterrent therapeutics for patients with chronic pain

Collegium (NASDAQ: COLL) is a specialty pharmaceuticals company focused on developing and commercializing abuse-deterrent products to address the growing problems associated with non-medical use, abuse, and misuse of prescription products. The company’s products are based on its proprietary DETERx® technology platform, which protects against misuse such as breaking, crushing, or dissolving. The company’s lead product, Xtampza ER, is an abuse-deterrent, extended-release formulation of oxycodone that has received Fast Track designation from the FDA. Collegium completed its IPO in 2015.

IPO in 2015 (NASDAQ: COLL)

Immunotherapeutics for treating and preventing infectious diseases and cancer

Corixa was a biopharmaceutical company focusing on innovative oncology and immunology-based products. The company received FDA approval for BEXXAR, an anti-CD20 antibody conjugated to a radioactive I-131 moeity, to treat non-Hodgkin’s lymphoma. Corixa also develped a novel adjuvant, MPL, that has been used in multiple investigational and approved vaccines. Corixa completed its IPO on NASDAQ in 1997 and was acquired by GSK in 2005.

IPO in 1997 (NASDAQ: CRXA); acquired by GlaxoSmithKline in 2005

Advancing new therapeutic options for pulmonary arterial hypertension

CoTherix was a biopharmaceutical company focused on licensing, developing, and commercializing therapeutics for cardiovascular diseases. The company licensed and developed Ventavis (iloprost), an inhaled prostacyclin analgoue for the treatment of pulmonary arterial hypertension that was approved by the FDA in 2004. Cotherix completed its IPO on NASDAQ in 2004 and was acquired by Actelion in 2006.

Acquired by Actelion in 2006

Frazier partnered with Frank Segrave to transform CPS into a leading diversified pharmacy services platform

CPS Solutions is a Frazier-backed pharmacy services company that was transformed from an inpatient-only pharmacy management business into a diversified enterprise with a high-growth outpatient specialty pharmacy platform. Frazier partnered with Executive in Residence Frank Segrave to lead the acquisition and expansion. Mr. Segrave previously led Silvergate Pharmaceuticals, another successful Frazier investment, and has held executive roles at Cardinal Health and Wal-Mart.

Acquired in 2024

Developer of two FDA-approved therapeutics for cardiovascular indications

CV Therapeutics was focused on the discovery, development, and commercialization of small molecule therapeutics to treat chronic cardiovascular diseases. The company gained FDA approval for two products, Ranexa (ranolazine) for angina and Lexiscan (regadenoson) for myocardial perfusion imaging. CV Therapeutics completed its IPO on NASDAQ in 1996 and was acquired by Gilead in 2009.

IPO in 1996; Acquired by Gilead Sciences in 2009

Innovative kinase inhibitor company advancing therapies for cancer

Deciphera Pharmaceuticals develops novel, highly selective kinase inhibitors designed to overcome treatment resistance in cancer. The company’s lead product, QINLOCK® (ripretinib), is approved for advanced gastrointestinal stromal tumors (GIST), and its pipeline includes vimseltinib for tenosynovial giant cell tumor and other proprietary kinase programs. Deciphera was acquired by Ono Pharmaceuticals in 2024.

Acquired by Ono in 2024

Working to advance a novel approach to agonist antibody therapeutics

Diagonal Therapeutics is a biotech company creating a new approach to discovering and developing agonist antibodies. The Company’s DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal’s emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Advancing covalent biologics to improve the treatment of cancer and other serious diseases

Enlaza is a San Diego, CA-based biotech developing novel technology for covalent protein targeting, a heretofore untapped opportunity. Similar to the manner in which covalent small molecule inhibitors offer a means to irreversibly bind the target, Enlaza is developing a suite of target-locking biologics that can be modularly- and irreversibly linked to a variety of effector molecules. Enlaza is building a pipeline of potential first-in-class covalent biologics with an initial focus in oncology.

Spinout of Ascendis developing sustained-release biologics for back-of-the eye ophthalmology indications

Eyconis is an ophthalmology-focused company developing technologies to enable sustained release of biologics following intravitreal injections. The company was co-founded by Ascendis and Frazier Life Sciences and has an exclusive license from Ascendis to TransCon technologies for ophthalmology indications. Eyconis’ goal is to significantly extend the time between intravitreal injections compared to current standards of care biologics to treat patients with wet AMD, DME, and other retinal diseases.

BridgeBio spinout focused on developing novel therapeutics for genetic and/or rare diseases

GondolaBio is a BridgeBio spinout developing early stage clinical and/or preclinical assets across a range of genetic and/or rare diseases, including; tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

A cancer immunotherapy company developing next-generation, personalized cancer therapeutics

Gritstone bio is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

IPO in 2018 (NASDAQ: GRTS)

Pioneering RIPTAC™ therapeutics, a new class of precision medicines, to defeat cancer

RIPTACs are bifunctional small molecules that selectively target tumors by holding a tumor-specific protein and a protein with essential function together in a trimeric complex involviing the formation of neo protein-protein-interactions. This mode of action results in abrogation of the essential protein function and subsequent cancer cell death. Halda’s lead program is an AR targeted RIPTAC being developed in mCRPC.

Focused on the development and commercialization of novel vaccines

HilleVax is a Frazier-founded company focused on the development and commercialization of novel vaccine candidates. The company has licensed rights from Takeda to develop and commercialize its norovirus vaccine candidate worldwide outside of Japan. HIL-214 is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

IPO in 2022 (NASDAQ: HLVX)

Developing novel precision immunotherapies to revolutionize treatment of autoimmune disease

Hillstar is developing potentially first-in-class biologics that specifically target and deplete pathogenic cells responsible for driving autoimmune disease, with the goal of providing durable relief and improving patient outcomes compared to traditional immunosuppressive therapies. The company’s lead program is targeting TRBV9+ T cells.

Developing precision therapies against hard-to-drug targets

Hummingbird Bioscience is focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes. Enabled by their proprietary Rational Antibody Discovery platform, the company discovers and engineers precision therapies against optimal yet elusive epitopes that have not been successfully drugged, unlocking novel mechanisms of action. The company is advancing a pipeline of potentially first- and best-in-class precision therapies in oncology and autoimmunity, in collaboration with global partners in academia and industry.

Precision oncology company developing integrated therapeutic (Rx) and diagnostic (Dx) approaches

Ignyta (NASDAQ: RXDX) is advancing the concept of “precision oncology” through development of targeted therapeutics in parallel with companion diagnostics to identify patients most likely to respond to a drug. The company has a broad pipeline, including lead product RXDX-101 which inhibits multiple kinases (including TrkA, TrkB, TrkC, ROS1, and Alk) which are frequently altered in a range of solid tumors. Ignyta completed its IPO on NASDAQ in 2014 and was acquired by Roche in 2018.

IPO in 2014; Acquired by Roche in 2018

Translating advances in epigenetics into therapeutics for hematologic diseases

Imago is developing therapeutics for hematologic diseases based on emerging insights into epigenetic regulation of disease pathways. Epigenetic proteins regulate expression of many (oftentimes hundreds) of downstream genes, and Imago is taking a targeted approach to address specific epigenetic alterations that can be drivers of disease. Imago was acquired by Merck in 2022.

IPO in 2021; Acquired by Merck in 2023

Developing next-generation antibody therapies for transthyretin (ATTR) amyloidosis.

Immutrin is a UK-based company advancing a differentiated monoclonal antibody designed to selectively target and remove pathogenic amyloid deposits, with the goal of reversing disease progression in ATTR cardiomyopathy. The company’s approach builds on emerging clinical validation for amyloid-clearing antibodies and aims to deliver best-in-class outcomes by addressing both the underlying pathology and organ dysfunction. FLS led Immutrin’s Series A financing to advance the company’s lead asset through clinical proof of concept in ATTR cardiomyopathy.

Advancing the first needle-free, patient-controlled patch for management of post-operative pain

Incline was founded in 2010 to develop IONSYS, a late-stage therapeutic licensed from J&J. IONSYS is an innovative, needle-free patch that delivers fentanyl for the short-term management of post-operative pain, representing an alternative to traditional intravenous patient-controlled analgesia. Incline was purchased by The Medicines Company in 2012, and The Medicines Company gained FDA approval for IONSYS in 2015.

Acquired by The Medicines Company in 2012

Developing first-in-class small molecule inhibitors of HSD17B13 for MASH and other liver diseases

Inipharm is a Frazier-founded company focused on discovering and developing therapies for severe liver diseases. The company is advancing a pipeline of small-molecule therapies that target the activity of HSD17B13, which is a genetically validated target in a range of liver diseases (alcoholic, non-alcoholic, viral, and genetic).

Ophthalmology-focused company advancing a pipeline of topical and intravitreal programs to treat inflammatory diseases

Iolyx Therapeutics is a Frazier-founded company to develop ophthalmic therapeutics for both the front-of and back-of-the-eye. The company’s lead program, ILYX-002, is a topical ophthalmic formulation of a first-in-class (for ophthalmology) anti-inflammatory to treat dry eye, including in patients with Sjogren’s and other systemic inflammatory conditions.

Biopharmaceutical company developing therapies for rare kidney diseases

Jade Biosciences is focused on discovering and developing novel therapeutics to treat serious, underserved kidney disorders. The company leverages deep expertise in renal biology and translational science to advance first-in-class and best-in-class programs addressing the underlying drivers of disease progression. The company completed a reverse merger with Aerovate in 2025 to gain public listing on NASDAQ.

Reverse merger in 2025

Co-investment with Frazier Growth Buyout shaping future pharma commercialization solutions

Knipper Health is a diversified pharmaceutical services platform specializing in sample management, patient services, and third party logistics. In 2024, Frazier Life Sciences invested alongside Frazier Growth Buyout – marking FLS’ third partnership with serial healthcare entrepreneur, Frank Segrave. The investment aims to support Knipper’s transformation into a fully integrated, end-to-end commercialization solution provider.

Developing and commercializing novel treatments for patients suffering from severe dermatological diseases

Krystal Biotech is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from debilitating dermatological diseases. Krystal has developed a proprietary gene therapy platform, the Skin TARgeted Delivery platform (or STAR-D platform), that consists of a patent-pending engineered viral vector and skin-optimized gene transfer technology to develop off-the-shelf treatments for dermatological diseases for which the company believes there are no known effective treatments. Krystal gained FDA approval for its lead program, Vyjuvek, in 2023 to treat dystrophic epidermolysis bullosa.

NASDAQ: KRYS

Precision oncology company developing potentially best-in-class, CNS-penetrant therapeutics

Lengo Therapeutics is Frazier-founded precision oncology company developing CNS-penetrant inhibitors of cancer driver mutations. The company is comprised of experts in kinase biology and drug discovery, and is advancing a pipeline of potentially best-in-class candidates for patients with, or at high risk of, brain metastases. Lengo was acquired by Blueprint Medicines in 2021.

Acquired by Blueprint Medicines in 2021

Next-generation incretin peptide therapeutics for type 2 diabetes

Marcadia was a spinout from The University of Indiana that focused on novel diabetes therapeutics. The company’s programs were based on novel insights into the incretin pathways (GLP-1, GIP, glucagon) from the lab of Richard DiMarchi, and the company formed multiple partnerships with Merck and Eli Lilly for these assets. Marcadia was acquired in 2010 by Roche.

Acquired by Roche in 2010

Developing orally bioavailable, non-nucleotide modulators of the STING pathway to treat cancer and infectious diseases

Mavupharma is a drug discovery and development company focused on novel approaches to selectively target the STING (stimulator of interferon genes) pathway, leveraging the innate immune system to treat cancer and infectious diseases. The company was founded by Frazier, and its leadership team includes Frazier Senior Advisor Mike Gallatin and Frazier EIRs Bob Baltera and Brian Farmer. Mavu was acquired by AbbVie in 2019.

Acquired by AbbVie in 2019

Maze Therapeutics is harnessing the power of genetics to transform the lives of patients

Maze Therapeutics is developing medicines designed to imitate the effects of rare, naturally occurring, protective genetic variants and help halt the progression and potentially reverse the effects of kidney disease. The most advanced lead program is directed against APOL1 kidney disease, and the second program targets SLC6A19 for phenylketonuria and chronic kidney disease. Maze completed its IPO in 2025.

IPO in 2025 (NASDAQ: MAZE)

Focused on Rare Endocrine Diseases

MBX seeks to address rare endocrine disorders with substantial unmet medical need. The company is built upon the medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, Ph.D., co-founder and chief scientific officer of MBX. MBX completed its IPO in 2024.

IPO in 2024 (NASDAQ: MBX)

Developing novel therapeutics to treat rare, cholestatic liver diseases

Mirum Pharmaceuticals is developing a novel approach for treating cholestatic liver diseases. The company’s lead asset, maralixibat, is a Phase 3-ready investigational oral drug with an established safety profile and strong Phase 2 efficacy data in orphan pediatric indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Mirum is led by Frazier EIR Chris Peetz. The company completed its IPO in 2019.

IPO in 2019 (NASDAQ: MIRM)

Committed to developing and commercializing new antibiotics to treat infectious diseases

Frazier Life Sciences originally invested in Zavante Therapeutics, a clinical late-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. In 2018, Zavante was acquired by Nabriva Therapeutics, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. In 2019, the U.S. FDA approved Nabriva’s oral and intravenous (IV) formulations of Xenleta (lefamulin) for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

Zavante Therapeutics acquired by Nabriva (NASDAQ:NBRV) in 2018

Focused on the development of potentially transformative oral therapies for major cardiometabolic diseases

NewAmsterdam Pharma Holding B.V. merged with Frazier Lifesciences Acquisition Company (FLAC, a Frazier-sponsored SPAC) to create NewAmsterdam Pharma Company N.V. NewAmsterdam’s mission is to improve patient care in populations with metabolic diseases where traditional therapies have not been sufficiently successful or well-tolerated. The company is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. NewAmsterdam believes the de-SPAC transaction (and related PIPE) provided them with sufficient capital to execute on a definitive Phase III program in LDL-C-lowering, and further evaluate obicetrapib’s benefits in reducing risk of Major Adverse Cardiac Events.

IPO in 2020, SPAC Merger in 2022 (NASDAQ: NAMS)

Drug development and commercialization for gastroenterology and urological diseases

Oceana was a specialty pharmaceuticals company focusing on inlicensing, developing, and commercializing therapeutics for gastroenterology and urological diseases. The company’s portfolio included the following products: 1) Deflux, a commercial-stage bulking agent indicated for treatment of children with vesicoureteral reflux; and 2) Solesta, a biocompatible bulking gel for treatment of fecal incontinence. Oceana received FDA approval for Solesta in 2011, and the company was subsequently acquired by Salix the same year.

Acquired by Salix Pharmaceuticals in 2011

Novel topical formulations for treatment of dental diseases

Orapharma is a specialty pharmaceuticals company focusing on developing and commercializing novel therapeutics to improve and maintain oral health. The company developed ARESTIN, an oral topical formulation of minocycline, that was approved by the FDA in 2001 for treatment of periodontal disease. Orapharma completed its IPO in 2000 and was acquired by J&J in 2002.

Acquired by Johnson & Johnson in 2002

Clinical-stage biopharmaceutical company advancing novel precision medicines for cancer by targeting historically undruggable intracellular pathways.

Parabilis is developing a pipeline of stabilized α-helical peptide therapeutics derived from its proprietary Helicon™ platform, designed to reach and modulate challenging intracellular targets that traditional modalities cannot effectively address. Its lead program, FOG-001 (zolucatetide), is a first-in-class direct inhibitor of the β-catenin:TCF interaction and is being evaluated in Phase 1/2 studies in solid tumors driven by Wnt/β-catenin pathway dysregulation.

Developing AAV gene therapies for the treatment of genetic central nervous system diseases

Passage Bio is a gene therapy company focused on the discovery and development of genetic medicines for monogenic central nervous system diseases. Passage was founded on adeno-associated virus (AAV) technologies developed in the laboratory of Dr. James Wilson at the University of Pennsylvania.

IPO in 2020 (NASDAQ:PASG)

Focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Phathom is a Frazier-founded company focused on developing novel therapeutics for the treatment of gastrointestinal acid-related disorders. The company has licensed rights from Takeda to develop and commercialize vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the United States, Canada, and Europe. Phathom completed its IPO in 2019, and vonoprazan was approved by the FDA in 2023 (brand name Voquezna)

IPO in 2019 (NASDAQ: PHAT)

Advancing therapeutics for thrombosis and hematologic diseases

Portola (NASDAQ: PTLA) was founded in 2003 to develop and commercialize novel therapeutics for cardiovascular and hematologic diseases. The company’s pipeline includes: 1) betrixaban, an oral once-daily Factor Xa inhibitor to prevent venous thromboembolism; 2) adnexanet alfa, a first-in-class recombinant, modified Factor Xa that is being developed as a Factor Xa inhibitor antidote; and 3) cerdulatinib, a dual inhibitor of Syk and JAK pathways for hematologic malignanices. Portola completed its IPO on NASDAQ in 2013.

IPO in 2013 (NASDAQ: PTLA)

Leading prescription dermatology company with broad portfolio for acne and atopic dermatitis

PreCision Dermatology was founded in 2010 as a spinout from fellow Frazier portfolio company Collegium Pharmaceutical. The company started with three commercial-stage dermatology products based on the company’s proprietary foam formulation technology. Over the next three years, the PreCision experienced tremendous growth through both internal R&D as well as a series of acquisitions to become one of the leading commercial prescription dermatology companies, with strong brands such as Locoid, Clindagel, Aurstat, and other products for acne and atopic dermatitis. PreCision was acquired by Valeant in 2014.

Acquired by Valeant Pharmaceuticals in 2014

Developing therapeutics for under-served endocrine and metabolic diseases

QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. The company’s lead product Osphena, a selective estrogen receptor modulator, was approved by the FDA in 2013 to treat dyspareunia.

Acquired by Shionogi in 2017

Spinout from Crinetics focused on radiopharmaceuticals against novel targets

Radionetics Oncology is focused on the discovery and development of novel precision radiopharmaceuticals for the treatment of a wide range of oncology indications. The company leverages Crinetics Pharmaceuticals’ core non-peptide, small molecule platform to direct therapeutic radioisotopes to selective peptide receptors expressed on tumors. Radionetics was co-founded by Crinetics, 5AM Ventures, and Frazier, and has launched with a pipeline of lead and drug candidates against multiple oncology targets.

Clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for inflammatory and immunologic diseases.

RAPT is advancing a pipeline of small molecules and biologics designed to modulate key immune pathways underlying allergic and inflammatory conditions. Its lead program, ozureprubart, is a half-life-extended anti-IgE monoclonal antibody in Phase IIb development with the potential to address food allergy and other IgE-mediated diseases. RAPT was acquired by GSK in 2026.

Acquired by GSK in 2026

Innovative biotechnology company developing therapies for severe, life-threatening rare diseases

Reata Pharmaceuticals developed novel therapeutics that modulate cellular metabolism and oxidative stress to treat serious neurological and rare diseases. The company’s lead product, Skyclarys® (omaveloxolone), became the first FDA-approved treatment for Friedreich’s ataxia in 2023, representing a major milestone for patients with this progressive neuromuscular disorder. Reata’s commitment to addressing diseases with limited or no existing therapies led to its acquisition by Biogen in 2023, advancing its mission to bring transformative medicines to rare disease communities.

Acquired by Biogen in 2023

Advancing novel therapeutics for the emerging threat of drug-resistant, Gram negative bacterial infections

Rempex was a leading developer of novel antibiotics, focusing on the emerging threat of drug-resistant Gram negative bacterial infections. The two most advanced assets in the company’s pipeline are: Carbavance, a combination of a novel beta lactamase inhibitor with a carbapenem for treatment of hospitalized patients with severe infections; and RPX-602, an improved formulation of Minocin IV. Rempex was acquired by The Medicines Company in 2013, and The Medicines Company gained FDA approval for RPX-602 in 2015.

Acquired by The Medicines Company in 2013

Small molecule therapeutics for autoimmune & inflammatory diseases and cancer

Rigel (NASDAQ: RIGL) is focused on discovery and development of therapeutics against novel targets implicated in autoimmune diseases, inflammatory diseases, and cancer. Rigel completed its IPO in 2000.

IPO in 2000 (NASDAQ: RIGL)

Developing innovative therapies for kidney disease patients in Greater China

SanReno Therapeutics is a joint venture spun out of Chinook Therapeutics to develop and commercialize kidney disease therapies that address significant unmet needs for patients in Greater China. The company’s lead assets are atrasentan and BION-1301, both in clinical trials for IgA nephropathy. SanReno was acquired by Novartis in 2024.

Acquired by Novartis in 2024

Developing and commercializing non-opioid approaches to treat pain

Frazier Life Sciences originally invested in Semnur Pharmaceuticals, a specialty pharmaceuticals company advancing novel non-opioid therapeutics for patients with chronic back pain. In 2019, Semnur merged with Scilex, a majority owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE). Scilex’s lead product is ZTlido 1.8%, a lidocaine topical delivery system which has been approved by the U.S. FDA to treat post-herpetic neuralgia. Scilex launched ZTLido in Q4 2018. Scilex is also developing SP-102, a non-opioid corticosteroid gel developed at Semnur, which is currently in Phase 3 pivotal studies for the treatment of lumbar radicular pain/sciatica and which has also been granted Fast Track status from the FDA.

Merger with Semnur Pharmaceuticals in 2019

Scorpion Therapeutics is pioneering the next generation of therapeutics for precision oncology

Scorpion Therapeutics is a fully integrated company developing novel precision therapeutics for oncology. Scorpion’s lead program, STX-478, is a mutant selective PI3Ka inhibitor that has shown promising efficacy and safety in cancer patients whose tumors have PI3Kα mutations. Scorpion was acquired by Lilly in 2024.

Acquired by Eli Lilly & Co. in 2025

Developing novel vector-delivered protein therapeutics for animal health

Scout Bio is a Frazier-founded company formed to discover, develop, and commercialize protein and monoclonal antibody therapeutics expressed via one-time intra-muscular injections of adeno-associated virus (AAV) vectors for animal health.

Acquired by Ceva Santé Animale in 2024

Advancing bispecific antibody drug conjugates (ADCs) in oncology.

Sidewinder Therapeutics is advancing a pipeline of bispecific ADCs designed to selectively target tumor cells and improve therapeutic index by enhancing tumor specificity and minimizing off-target toxicity. The company’s approach integrates novel antibody engineering with optimized payload delivery to address limitations of first-generation ADCs and expand the range of druggable oncology targets. FLS co-led Sidewinder’s $137M Series B round to support advancement of the company’s lead bispecific ADCs into the clinic.

Developing momelotinib to treat myelofibrosis and related comorbidities

Sierra Oncology (NASDAQ: SRRA) [formerly ProNAi Therapeutics (NASDAQ: DNAI)] is a clinical stage company advancing momelotinib to treat myelofibrosis. Momelotinib is a JAK2 inhibitor that uniquely addresses anemia that is both a hallmark of myelofibrosis as well as a common side effect of other JAK inhibitor therapeutics. Sierra was acquired by GSK in 2022, and momelotinib was approved in 2023 as brand name Ojjaara.

IPO in 2015 (NASDAQ: SRRA); Acquired by GSK in 2022

Delivering high-quality medications developed specifically for pediatric patients

Silvergate is a specialty pharmaceuticals company focusing on developing and commercializing pediatric medications. The company’s approach is to innovate therapeutics that offer greater dosing accuracy, safety, and availability than currently available options. Silvergate’s lead product, Epaned, was approved by the FDA in 2013 as the first and only enalapril powder for oral solution. The company also received FDA approval in 2016 for Qbrelis, which is an oral solution of Lisinopril for pediatric patients 6 years of age and older. Silvergate was acquired by CutisPharma in 2019.

Acquired by CutisPharma in 2019

Focused on the development of regulatory T cell therapies

Sonoma is developing adoptive T reg cell therapies for autoimmune and inflammatory diseases. Using genome editing and target-specific cell therapy, Sonoma is focused on developing a best-in-class platform across the entire spectrum of T reg cell therapeutic capabilities. The company brings together expertise and proprietary methodologies for the discovery and development of disease-modifying and curative therapies.

Targeted oncology company developing and commercializing therapies for rare cancers

SpringWorks Therapeutics is a precision oncology company focused on genetically defined cancers and rare tumor types. The company advanced nirogacestat, a gamma-secretase inhibitor for desmoid tumors, and mirdametinib, a MEK inhibitor for plexiform neurofibromas, through late-stage clinical development. SpringWorks achieved FDA approval of nirogacestat (brand name Ogsiveo) in 2023, marking the first approved therapy for desmoid tumors, and continues to expand its portfolio of targeted oncology programs in partnership with leading biopharmaceutical companies. Merck KGaA acquired Springworks in 2025.

Acquired by Merck KGaA in 2025

Innovative biotech company creating and launching therapies for rare diseases

Star Therapeutics is a biotechnology company developing transformative therapies for rare diseases. The company’s lead program is a Protein S modulating monoclonal antibody being developed for patients with Von Willebrand Disease and other bleeding disorders.

Fibrosis therapeutics targeting the TGF-beta pathway

Stromedix was founded in 2007 to develop novel therapeutics to treat fibrosis. The company’s lead asset, STX-100, is a monoclonal antibody against alpha(V)beta(6), which is involved in TGF-beta signaling. TGF-beta has linked to a number of fibrotic diseases, including idiopathic pulmonary fibrosis, and STX-100 has been shown to selectively disrupt the TGF-beta pathway. Stromedix was acquired by Biogen Idec in 2012.

Acquired by Biogen Idec in 2012

Developing first-in-class CNS-penetrant TYK2 inhibitor therapeutics

Sudo Biosciences is a Frazier-founded company committed to discovering and developing CNS penetrant, selective inhibitors of TYK2 to treat multiple sclerosis and other neuroinflammatory and neurodegenerative diseases.

Developing innovative therapies for Demodex blepharitis and eye care

Tarsus Pharmaceuticals is focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions. Tarsus gained FDA approval for its lead product, Xdemvy (lotilaner ophthalmic solution) in 2023 as the first and only prescription therapeutic to treat Demodex blepharitis. Tarsus completed its IPO in 2020.

IPO in 2020 (NASDAQ: TARS)

Targeting serious diseases of immuno-inflammation and fibrosis

Tobira (NASDAQ: TBRA) is developing novel therapeutics to treat liver disease, fibrosis, and inflammatory diseases. The company’s lead product, cenicriviroc, is a first-in-class dual inhibitor of CCR2 and CCR5, both of which are involved in the cycle of inflammation and fibrosis. Tobira is advancing cenicriviroc to treat non-alchoholic steatohepatitis (NASH) as one of the first immunomodulatory approaches for NASH. Tobira was acquired by Allergan in 2016.

Acquired by Allergan in 2016

Developing a new class of potentially transformative mRNA medicines

Translate Bio is a clinical stage biotechnology company developing a new class of potentially transformative mRNA based medicines to treat diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform (MRT), Translate is seeking to address a wide range of diseases that are not well managed with existing protein or gene replacement therapies. The company’s lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. Translate was acquired by Sanofi in 2021.

Acquired by Sanofi in 2021

Clinical-stage company developing therapies for chronic pruritus and other neurologically mediated conditions

Trevi Therapeutics is focused on developing therapies for chronic cough. Its lead candidate, Haduvio® (nalbuphine extended-release), is being evaluated as a potential treatment for idiopathic pulmonary fibrosis (IPF) related cough as well as refractory chronic cough (RCC), conditions with high unmet need and limited treatment options.

Developing innovative therapies for the treatment of cancer

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.

Acquired by Pfizer in 2021

Next-generation protein therapeutics for autoimmune and hematologic diseases

Trubion focused on creating protein therapeutics for autoimmune and hematologic oncology diseases. The company’s products were based on several novel technology platforms to enhance or extend antibody-based therapeutics. Trubion completed its IPO on NASDAQ in 2006 and was acquired by Emergent BioSolutions in 2010.

Acquired by Emergent BioSolutions in 2010

Building a pipeline of highly stable ADCs leveraging proprietary linker, conjugation, and payload technologies

Tubulis utilizes innovative proprietary technologies and diease-specific biological understanding to produce custom-matched protein-drug conjugates. Their objective is to enhance the therapeutic scope of antibody-drug conjugates (ADCs) by improving design flexibility and addressing challenges related to toxicity, efficacy, and targeted indications.

Early pioneer in discovery and development of therapeutics acting through regulation of gene expression

Tularik was focused on drug discovery related to cell signaling and the control of gene expression. Tularik completed its IPO in 1999 and was acquired by Amgen in 2004.

IPO in 1999; Acquired by Amgen in 2004

Developing best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases

Vaxcyte (formerly SutroVax) is a vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases. The company is leveraging an exclusive license to Sutro Biopharma’s Xpress cell-free protein synthesis platform to develop vaccines with heightened immunity and broader protection than can be attained with existing platforms. Vaxcyte’s lead program is a potentially best-in-class pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease.

IPO in 2020 (NASDAQ: PCVX)

Rare disease company developing therapies for severe gastrointestinal disorders

VectivBio focused on developing innovative treatments for rare, chronic, and life-threatening gastrointestinal diseases. Its lead program, apraglutide, is a next-generation GLP-2 analog designed to improve intestinal absorption in patients with short bowel syndrome (SBS). The company’s scientific and clinical strategy emphasized durable efficacy, patient quality of life, and long-term safety. VectivBio was acquired by Ironwood Pharmaceuticals in 2023, enabling the continued advancement of apraglutide toward commercialization and expanding Ironwood’s leadership in rare GI disorders.

Acquired by Ironwood in 2023

Developing new immunotherapies to advance the cancer treatment paradigm

VentiRx is one of the leading companies developing therapies to activate the immune system to address solid tumors. The company’s lead product, motolimod, is a selective agonist of TLR-8 and stimulates myeloid-derived dendritic cells to produce and release inflammatory mediators to activate an immune response. VentiRx has entered into a worldwide strategic collaboration with Celgene for motolimod and is in clinical studies to treat ovarian and head & neck cancer.

Acquired by Celgene in 2017

Respiratory-focused biopharmaceutical company developing novel therapies for chronic lung diseases

Frazier Life Sciences’ Public Fund invested in Verona Pharma to support the advancement of ensifentrine, a first-in-class dual PDE3 and PDE4 inhibitor for chronic obstructive pulmonary disease (COPD) and other respiratory indications. The company’s lead program demonstrated clinically meaningful improvements in lung function and symptom control in pivotal Phase 3 trials. Verona completed its U.S. regulatory filing in 2024, with FDA approval of ensifentrine (brand name Ohtuvayre) in 2025, marking an important new treatment option for COPD patients. Verona was acquired by Merck in 2025.

Acquired by Merck in 2025

Clinical-stage biopharmaceutical company developing novel oral therapies for movement disorders, including dystonia and Parkinson’s disease.

Vima is a Boston-based company advancing VIM0423, a potential first-in-class once-daily oral therapy designed to selectively target muscarinic cholinergic receptors in the brain to treat dystonia and related movement disorders. Vima’s approach aims to address the shared underlying biology of these disorders, which is caused by an imbalance between dopamine and acetylcholine signaling in the brain, leading to excessive cholinergic activity. Vima’s approach aims to deliver a well-tolerated, effective oral treatment option for patients with significant unmet need in neurological motor control.

Developing and commercializing therapeutics for infectious and orphan diseases

Viropharma was originally an anti-viral therapeutics discovery and development company that eventually became one of the leading specialty pharmaceutical companies focusing on a range of orphan and infectious diseases. Viropharma completed its IPO in 1996 and was acquired by Shire in 2013.

IPO in 1996; Acquired by Shire in 2013

Drug development for obesity and sexual health

VIVUS (NASDAQ: VVUS) is a biopharmaceutical company developing therapeutics to treat obesity, sexual health, and other diseases. VIVUS completed its IPO on NASDAQ in 1994.

IPO in 1994 (NASDAQ: VVUS)

Discovering and developing therapeutics for neurological diseases

XenoPort (NASDAQ: XNPT) is a biopharmaceutical company focusing on developing on commercializing a portfolio of internally discovered products for neurological disorders. The company’s lead product, HORIZANT (gabapentin encarbil), was approved by the FDA in 2011 to treat restless leg syndrome. XenoPort completed its IPO on NASDAQ in 2005.

IPO in 2005 (NASDAQ: XNPT)

Early pioneer in recombinant protein-based therapeutics

Zymogenetics was a biopharmaceutical company focusing on discovery, development, and commercialization of protein-based therapeutics to treat cardiovascular, autoimmune, and viral diseases. Zymogenetics completed its IPO on NASDAQ in 2002 and was acquired by BMS in 2010.

IPO in 2002; Acquired by BristolMyersSquibb in 2010